Intelligence / Healthtech / De Novo Grants / Brixton Biosciences
Approvalsnovel device granted (FDA De Novo)21 Aug 2026
Brixton Biosciences
21 Aug 2026: Novel device granted (FDA De Novo) · ReneuRx (Neural Ice). Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 21 Aug 2026
- Device
- ReneuRx (Neural Ice)
- Specialty
- Orthopedic
- Product Code
- SJA
- Country
- United States
- Location
- Cambridge, MA
- Submitted
- 2025-12-15
- Reference
- DEN250067
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Brixton Biosciences
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Brixton Biosciences in our registers.
More in Orthopedic
De Novo Grants
17 JulStryker Endoscopynovel device granted (FDA De Novo) · SportSuite Vision SoftwareApprovals6 JulSmith & Nephew, Inc.novel device granted (FDA De Novo) · TESSA Spatial Surgery System; INTELLIO Tablet (72205455)Approvals17 JunFziomed, Inc.novel device granted (FDA De Novo) · Oxiplex®Approvals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.